Topotecan

Generic Name: Topotecan

Brand Names: Hycamtin, Potactasol, Topotecan Hospira

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₂₃N_₃O_₅

CAS Number: 123948-87-8

Unique Ingredient Identifier: 7M7YKX2N15

Background: An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.

Indication: 用于小细胞肺癌（SCLC）和一线治疗失败的晚期转移性卵巢癌。

Associated Conditions: Acute Myeloid Leukemia, Ewing's Sarcoma, Refractory Neuroblastoma, Metastatic Rhabdomyosarcoma, Recurrent Stage IVB Cervical Cancer, Refractory CNS lymphoma, Refractory CNS malignancy, Refractory, metastatic Ovarian cancer, Relapsed Platinum Sensitive Small Cell Lung Cancer (SCLC)

Associated Therapies: -

Clinical Trials

A Phase I/II Study of Induction Chemotherapy With Daunorubicin, Cytarabine, Topotecan and Etoposide

Phase 1

Completed

Conditions: Leukemia

Interventions: Drug: Cytarabine
Drug: Daunorubicin
Drug: Etoposide
Drug: Topotecan

First Posted Date: 2003-05-07

Last Posted Date: 2012-09-25

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 41

Registration Number: NCT00005793

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Phase 2

Completed

Conditions: Extensive Stage Small Cell Lung Cancer

Interventions: Biological: G-CSF
Drug: Cisplatin
Drug: Irinotecan
Drug: Etoposide
Drug: Topotecan

First Posted Date: 2003-04-09

Last Posted Date: 2023-07-05

Lead Sponsor: Eastern Cooperative Oncology Group

Target Recruit Count: 140

Registration Number: NCT00057837

Locations: 🇺🇸
Elkhart General Hospital, Elkhart, Indiana, United States
🇺🇸
Carle Cancer Center at Carle Foundation Hospital, Urbana, Illinois, United States
🇺🇸
St. Luke's Regional Medical Center, Sioux City, Iowa, United States

and more 75 locations

Topotecan Hydrochloride in Treating Children With Meningeal Cancer That Has Not Responded to Previous Treatment

Phase 2

Completed

Conditions: AIDS-related Diffuse Large Cell Lymphoma
AIDS-related Diffuse Mixed Cell Lymphoma
AIDS-related Diffuse Small Cleaved Cell Lymphoma
AIDS-related Immunoblastic Large Cell Lymphoma
AIDS-related Lymphoblastic Lymphoma
AIDS-related Peripheral/Systemic Lymphoma
AIDS-related Primary CNS Lymphoma
AIDS-related Small Noncleaved Cell Lymphoma
Childhood Diffuse Large Cell Lymphoma
Childhood Immunoblastic Large Cell Lymphoma

Interventions: Drug: topotecan hydrochloride
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-02-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 77

Registration Number: NCT00005811

Locations: 🇺🇸
Children's Oncology Group, Arcadia, California, United States

Chemotherapy in Treating Children With Recurrent or Refractory Sarcomas

Phase 2

Completed

Conditions: Sarcoma

Interventions: Drug: topotecan hydrochloride

First Posted Date: 2003-01-27

Last Posted Date: 2013-02-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 125

Registration Number: NCT00003745

Locations: 🇺🇸
Marlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States
🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸
Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States

and more 231 locations

Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer

Phase 1

Completed

Conditions: Brenner Tumor
Ovarian Clear Cell Cystadenocarcinoma
Ovarian Endometrioid Adenocarcinoma
Ovarian Mixed Epithelial Carcinoma
Ovarian Mucinous Cystadenocarcinoma
Ovarian Serous Cystadenocarcinoma
Ovarian Undifferentiated Adenocarcinoma
Stage III Ovarian Epithelial Cancer
Stage IV Ovarian Epithelial Cancer

Interventions: Drug: paclitaxel
Drug: cisplatin
Drug: topotecan hydrochloride
Biological: filgrastim

First Posted Date: 2003-01-27

Last Posted Date: 2013-01-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT00002913

Locations: 🇺🇸
Gynecologic Oncology Group of Arizona, Phoenix, Arizona, United States

UCN-01 and Topotecan in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer

Phase 1

Completed

Conditions: Fallopian Tube Cancer
Ovarian Cancer
Primary Peritoneal Cavity Cancer

Interventions: Drug: 7-hydroxystaurosporine
Drug: topotecan hydrochloride

First Posted Date: 2003-01-27

Last Posted Date: 2016-06-23

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 33

Registration Number: NCT00045175

Locations: 🇨🇦
Cancer Care Ontario-London Regional Cancer Centre, London, Ontario, Canada
🇨🇦
Margaret and Charles Juravinski Cancer Centre, Hamilton, Ontario, Canada
🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada

Phase I Study of Intrathecal Topotecan

Phase 1

Completed

Conditions: Leukemia
Lymphoma
Meningeal Neoplasms

First Posted Date: 2002-12-10

Last Posted Date: 2008-03-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT00001333

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

Oral Topotecan Versus Intravenous Docetaxel In Pretreated, Advanced Non-Small Cell Lung Cancer

Phase 3

Completed

Conditions: Non-Small-Cell Lung Cancer

First Posted Date: 2002-11-20

Last Posted Date: 2013-03-04

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 760

Registration Number: NCT00049998

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

A Bioequivalence Study of Two Oral Formulations of Topotecan in Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Lung Cancer, Small Cell
Solid Tumor Cancer

Interventions: Drug: topotecan

First Posted Date: 2002-09-23

Last Posted Date: 2017-05-30

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1

Registration Number: NCT00046111

Locations: 🇨🇦
GSK Investigational Site, Ottawa, Ontario, Canada

The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)

Phase 2

Completed

Conditions: Small Cell Lung Cancer
Lung Cancer, Small Cell

First Posted Date: 2002-08-15

Last Posted Date: 2017-05-31

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 60

Registration Number: NCT00043862

Locations: 🇺🇸
GSK Investigational Site, Wausau, Wisconsin, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy